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Abstract
Dyslipidemia is common in chronic hemodialysis patients and its underlying mechanism is complex. Hemodialysis causes
an imbalance between antioxidants and production of reactive oxygen species, which induces the oxidative stress and
thereby may lead to accelerated atherosclerosis. Statins have been found to be little effective in end-stage kidney disease
and other lipid-lowering therapies have been only scarcely studied. The study aimed to assess the effect of low-dose
fenofibrate therapy on plasma lipids and redox status in long-term hemodialysis patients with mild hypertriglyceridemia.
Twenty seven chronic hemodialysis patients without any lipid-lowering therapy were included in a double-blind
crossover, placebo-controlled study. The patients were randomized into two groups and were given a sequence of either
100 mg of fenofibrate per each hemodialysis day for 4 weeks or placebo with a week-long wash-out period between
treatment periods. Plasma lipids, high sensitive C-reactive protein (CRP), urea, creatinine, electrolytes, phosphocreatine
kinase (CK), GOT, GPT and plasma thiols (total and free glutathione, homocysteine, cysteine and cysteinylglycine) were
measured at baseline and after each of the study periods. Plasma aminothiols were measured by reversed phase HPLC
with thiol derivatization with 2-chloro-1-methylquinolinium tetrafluoroborate.
Fenofibrate therapy caused a significant decrease of total serum cholesterol, LDL cholesterol and triglycerides and an
increase of HDL cholesterol. The treatment was well tolerated with no side-effects but there was a small but significant
increase of CK not exceeding the upper limit of normal range. There were no changes of serum CRP, potassium, urea,
and creatinine and liver enzymes during the treatment. Neither total nor total free cysteinylglycine and cysteine changed
during the study but both total and free glutathione increased during the therapy with fenofibrate and the same was
observed in case of plasma homocysteine.
T h es t u d ys h o w st h a tat r e a t m e n tw i t hr e d u c e df e n o f i b r a t ed o s ei ss a f ea n de f f e c t i v ei nr e d u c i n gs e r u mt r i g l y c e r i d e sa n d
cholesterol in chronic dialysis patients and may shift plasma aminothiol balance towards a more antioxidative pattern.
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Introduction
The patients with end-stage kidney disease are character-
ized by accelerated atherosclerosis and greatly increased
cardiovascular morbidity and mortality [1,2]. Both conven-
tional and non-conventional cardiovascular risk factors
such as lipoprotein (a), homocysteine, inflammation, oxi-
dative stress and a variety of uremic toxins may be
involved in the pathogenesis of cardiovascular disease in
this population [2,3]. The current unifying pathophysio-
logical concepts of atherosclerosis in subjects with and
without renal function impairment emphasize the role of
chronic inflammation and oxidative stress in the arterial
wall in this process [3,4].
Fibrates have been used for the treatment of lipid disor-
ders for more than 40 years largely due to the effective
lowering of serum triglyceride levels. Effects of this class
of drugs have been studied in several large clinical trials
with cardiovascular end-points including the seminal
Fenofibrate Intervention and Event Lowering in Diabetes
(FIELD) trial [5]. Despite their well proven renoprotective
* Correspondence: nefro@wp.pl
1Department of Nephrology, Hypertension and Kidney Transplantation,
Medical University of Łódź, Łódź, Poland
3Department of Nephrology, Hypertension and Kidney Transplantation,
Medical University of Łódź, University Hospital #1, Kopcińskiego 22, 90-153,
Łódź, Poland
Full list of author information is available at the end of the article
© 2012 Makówka et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under theterms of the Creative
Commons Attribution License(http://creativecommons.org/licenses/by/2.0),which permits unrestricted use, distribution,
andreproduction in any medium, provided the originalwork is properly cited.
Makówka et al. Lipids in Health and Disease 2012, 11:47
http://www.lipidworld.com/content/11/1/47effect as shown by a reduction of the progression to
microalbuminuria in diabetic patients in the Diabetes
Atherosclerosis Intervention Study (DAIS) [6] a use of
most fibrates including fenofibrate has been limited to
patients with normal or only mildly decreased glomerular
filtration rate due to the accumulation of their metabolites,
increase of serum creatinine and higher risk of rhabdo-
myolysis [7-9]. As the result the patients with low GFR
glomerular filtration rate, i.e. chronic kidney disease stage
3-5day were excluded from all large trials with fibrates
precluding an assessment of their efficacy and safety in
this clinical setting even with reduced dosing [8,10]. Mixed
dyslipidemia associated with chronic kidney disease is
characterized by hypertriglyceridemia and low serum
HDL-cholesterol [10] that make this population of
patients good candidates for fibrate treatment.
The lack of the clinical trial experience with fibrates in
the patients with low glomerular filtration rate contrasts
both with their renoprotective effects shown in experi-
mental studies [11-13] as well as with everyday practice
[14]. The authors of one recent study found that fenofi-
brate was chronically used by 34 of 305 hemodialysis
patients from two centers in Taiwan [14]. On the other
hand several series of case reports of rhabdomyolysis in
patients with renal failure treated either with fibrates in
the doses used in patients with normal GFR or treated
simultaneously with statins have been published [7]. The
patients with end-stage renal disease treated with
hemodialysis may be particularly susceptible to toxic
effects of fibrates since in the absence of the removal of
their metabolites with urine only about 10% of a single
fenofibrate dose was cleared from the blood by
hemodialysis resulting in a substantially prolonged plasma
half-life of its major metabolite fenofibric acid [15,16].
Since there have been no randomized trials in patients
with renal failure treated with fibrates we decided to carry
out a pilot placebo-controlled study with greatly reduced
dose of fenofibrate in a group of chronic dialysis patients
to assess the safety and lipid lowering efficacy of this drug.
In addition, since some beneficial cardiovascular effects of
fibrates that are potent PPAR-alfa agonists have been
attributed to non-lipid lowering mechanisms [17] we
decided to study the effect of fenofibrate on a biomarker
of inflammation, i.e. high sensitive C-reactive protein and
on plasma aminothiol redox status, i.e. a novel marker of
oxidative stress [18].
Patients and methods
In this double-blind randomized cross-over pilot single-
center study 27 chronic Caucasian hemodialysis patients
were included (18 men and 9 women, mean age
58.5±13 years, time on dialysis 3.9±4.0 years).
The patients were qualified if they fulfilled the following
inclusion criteria: age >18 years, at least 12 months on
chronic hemodialysis therapy with three dialysis sessions
per week, total cholesterol concentration ≥200 mg/dL or
LDL-cholesterol ≥120 mg/dL and serum triglycerides
≥150 mg/dL, residual diuresis <500 ml/day. The exclusion
criteria were as follows: use of any fibrate or statin within
6 months prior to the study, previous intolerance of
fibrates or statins, chronic immunosuppressive and/or
steroid therapy, diabetes mellitus requiring insulin ther-
apy, arterial hypertension resistant to treatment, cancer,
acute or chronic inflammatory diseases, psychiatric disor-
ders, history of poor compliance.
After being qualified the patients underwent a brief
training aimed at explaining the study procedures, use of
concomitant medications, compliance with pharmaco-
therapy and the necessity of reporting all the potential
side-effects of the therapy at each dialysis to the treating
physician.
At baseline visit in the morning of the day of a sched-
uled mid-week dialysis session the following parameters
were measured in fasting patients: blood pressure with
standard mercury sphygmomanometer (in triplicate),
body height and body weight for body mass index (BMI)
calculation, serum creatinine, urea, sodium, potassium,
chloride, albumin, total, LDL and HDL cholesterol, tri-
glycerides, phosphocreatine kinase, asparagine amino-
transferase and C-reactive protein (high-sensitive assay).
The blood was withdrawn immediately prior to dialysis
after the vascular access cannulation. The HD prescrip-
tion for all patients consisted of the treatment time of
240 min three times per week in a morning dialysis shift,
blood flow of 200–250 ml/min and dialysate flow of
500 ml/min. In all cases low-flux modified cellulose
(Hemophane) membranes were used (Alwall GFS Plus,
Gambro, Lund, Sweden). Dialyzers were not reprocessed.
Dialyzer surfaces were chosen according to the patient’s
body surface area and the following sizes were used 1.1,
1.3 and 1.7 m
2 resulting with ultrafiltration coefficients
of 5.5, 6.8 and 9.4 ml/h/mmHg, respectively. Plasma total
and reduced fractions of aminothiols (homocysteine, cyst-
eine, cysteinylglycine and glutathione) were assessed with
high-performance liquid chromatography (HPLC). Blood
was withdrawn to the Sarstedt Monovette
W system to pre-
vent hemolysis. Separate prechilled EDTA-containing tubes
were used for a collection of blood for the assessment of
total and free aminothiol fractions. The blood for the
measurement of total and total free aminothiol plasma
concentration was immediately centrifuged in 4°C for 10
min (2 500 g) and the plasma was frozen until measure-
ments [19] at −30°C for a maximum of 1 week.
All other biochemical parameters were assessed with
standard automated laboratory methods in the local
laboratory.
All study procedures lasted 63 days. The above listed
measurements were repeated three times, i.e. at baseline,
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after 63 days when the patients completed the second
treatment period. The patients were randomly assigned to
receive placebo followed by fenofibrate or fenofibrate
followed by placebo. Fenofibrate (or identically looking
placebo tablets) was given in a single morning dose of
100 mg on a dialysis day shortly after an arrival to the
center. The treatments were separated by a 7 day wash-
out period. The study protocol is depicted in Figure 1.
The study protocol was approved by the Ethics Com-
mittee of the Medical University of Łódź, Poland.
All other medications that were chronically used by
the patients were administered in unchanged doses for
the whole duration of the study.
To compare the results of the measurements of plasma
total and total free aminothiol fractions in hemodialysis
patients to the reference values in subjects with normal
renal function we used the results from the historic cohort
of healthy volunteers (4 men and 4 women, mean age
38±13 years) as characterized in our previous study [19]
Statistical analysis
All results are expressed as mean±SD. Statistical signifi-
cance was defined at p<0.05. The normality of data
distribution was checked with Shapiro-Wilk test, and non-
normally distributed data were logarithmically transformed
before analysis. Within-group comparisons were made
using a t-test or Wilcoxon’s test. The Pearson or Spearman
correlation coefficient was used to assess relations between
the variables. Statistical analysis of treatment outcome was
carried out using the parametric approach to crossover trials
including the evaluation of potential carryover effects on
plasma lipids. Statistical analysis was performed using the
StatSoft, Inc. Tulsa, OK, USA (2010). STATISTICA (data
analysis software system), version 9.1. www.statsoft.com.
Results
The treatment with the study drug was well-tolerated
and no adverse effects of fenofibrate therapy were
observed. All 27 patients that had been initially qualified
completed the whole study.
No significant changes of blood pressure and body mass
index were found throughout the study. There were also
no significant changes of serum potassium, creatinine,
urea and albumin and blood count with the exception of
the leukocyte number that significantly decreased after
fenofibrate but not after placebo when compared to base-
line (6.4±2.0 and 6.6±2.0, respectively vs. 5,7±1.8 x 10
9;
p<.01). There was a small but significant decrease of
serum sodium after placebo but not after fenofibrate ad-
ministration. Aspartate aminotransferase was within the
normal range and remained unchanged for the whole
study. The same was also observed in case of alanine ami-
notransferase. In contrast, creatine phosphokinase signifi-
cantly increased during fenofibrate but not during placebo
administration. Despite the significant increase of creatine
phosphokinase its concentration remained in the normal
range in each subject. Baseline and post-treatment results
of blood pressure measurements and basic biochemical
parameters are shown in Table 1.
Mean baseline CRP was increased but there were no
changes in its concentration throughout the study.
There were significant changes of all lipid fractions
assessed in the study during the treatment with fenofibrate.
Fenofibrate caused a significant decrease of total serum
cholesterol (18.9% from the baseline valeu), LDL choles-
terol (26%) and triglycerides (36.7%) and an increase of
HDL cholesterol (12.1%). In contract placebo did not in-
duce any significant changes of serum lipid concentration
(Figure 2).
Table 2 shows plasma concentration of total aminothiols
(glutathione, homocysteine, cysteine and cysteinylglycine).
At baseline total plasma glutathione was lower in dialysis
patients than in healthy controls but plasma homocyst-
eine, cysteine and cysteinylglycine were all higher. 28-day
treatment with fenofibrate caused a significant increase of
total plasma glutathione (p=−.02) and homocysteine
(p=,04) but not cysteine and cysteinylglycine.
Figure 1 Diagram of study design.
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thiols. Baseline plasma glutathione was lower and homo-
cysteine, cysteine and cysteinylglycine higher in dialysis
patients than in healthy controls. During the treatment
with fenofibrate plasma free glutathione fraction
increased significantly (p=.01) and free homocysteine
decreased (p=.04). Both cysteine and cysteinylglycine
were unchanged. Placebo did not have any effect on total
free thiol fractions.
Figure 3 shows the ratio of free to total aminothiols
(aminothiol redox status) during the study. The treat-
ment with fenofibrate caused a significant decrease of
the ratio of free to total glutathione (p=.01) and an in-
crease in the ratio of free to total homocysteine (p=.02).
No significant effect of placebo was seen in case of all
aminothiols. The same was true during fenofibrate ad-
ministration that did not induce any changes in the
ratios of free to total cysteine and cysteinylglycine.
Discussion
There are fundamental differences between the epidemi-
ology of cardiovascular disease in end-stage renal disease
and non-renal population [1,2]. Non-traditional risk
factors may be responsible for a large part of cardiovas-
cular mortality in chronic dialysis patients [1,2,20,21].
Furthermore the vascular pathologies commonly seen in
dialysis patients may differ from typical atherosclerotic
changes largely due to intensive medial and not only
intimal calcification [22]. Both these processes may how-
ever share the same pathogenesis including chronic
inflammation and oxidative stress [1,22]. C-reactive pro-
tein has been found to be a good biomarker of cardio-
vascular events and mortality both in the patient with
and without renal disease [23]. There is also a good body
Table 1 Blood pressure and basic biochemistry at
baseline and after the 28-day treatment with fenofibrate
or placebo
Parameter Baseline After Placebo After
Fenofibrate
Systolic blood
pressure [mmHg]
138±17 137±12 134±11
Diastolic blood
pressure [mmHg]
91±22 92±18 93±23
S-sodium [mmol/L] 139±3 137±3* 138±3
S-potassium [mmol/L] 5.1±0.9 5.1±0.8 5.2±0.8
S-albumin [g/L] 37.9±3.4 38.4±2.8 38.3±3.3
S-urea [mg/dL] 128.2±36.0 134.0±28.1 139.1±28.9
S-creatinine [mg/dl] 8.7±2.4 8.8±2.3 8.8±2.3
S-GOT [IU/L] 21.1±12.8 22.6±9.1 23.3±22.6
S-Creatine kinase [IU] 78.9±48.8 72.9±49.7 95.3±63.9#
S-CRP [mg/L] 6.4±5.2 7.2±7.6 7.9±9.1
# p=0.01 vs baseline; * p<0.05 vs baseline
Figure 2 Plasma lipids at baseline and after the 28-day treatment with fenofibrate or placebo.
Table 2 Plasma concentration of total aminothiols
(glutathione, homocysteine, cysteine and
cysteinylglycine) at baseline and after the 28-day
treatment with fenofibrate or placebo
Parameter Healthy
controls*
Baseline After
Placebo
After
Fenofibrate
Glutathione
[nmol/mL]
11.9±4.9 5.6±1.4 5.6±1.6 6.5±1.7
#
Homocysteine
[nmol/mL]
11.3±3.2 24.2±12.0 26.9±13.1 29.4±20.2
##
Cysteine
[nmol/mL]
275±99 535±105 552±107 542±106
Cysteinylglycine
[nmol/ml]
25±7 58±12 56±10 56±14
* healthy controls – historic cohort from Bald E et al. [19]
# p=0.02 vs baseline; ## p=0.04 vs baseline
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reactive protein levels confirming therefore its anti-
inflammatory effect [17,24], however the effect of this
drug on cardiovascular endpoints, i.e. mortality is still a
subject of controversy in particular after the publication
of the final results of FIELD study [5] and a more recent
Action to Control Cardiovascular Risk in Diabetes (AC-
CORD) trial [25,26]. In our study we were not able to
show any significant effect of fenofibrate on a marker of
inflammation, i.e. the serum C-reactive protein however
there was a decrease in a number of leukocytes that is
however much less sensitive marker of the chronic
inflammatory process.
Reactive oxygen species may play an important role in
the pathogenesis of renal failure and its complications
since it was found that they are generated by most uremic
toxins that possess strong redox properties [27]. This no-
tion is corroborated by the finding of increased serum
concentration of major aminothiols such as homocysteine
and cysteine and decreased levels of glutathione in
patients with chronic kidney disease when compared to
subjects with normal renal function [28-30].
Both homocysteine and cysteine has been implicated
in the pathogenesis of atherosclerosis through their
effects on endothelial dysfunction and pro-thrombotic
action [31,32]. Therefore homocysteine and cysteine are
recognized as the biomarkers of cardiovascular disease
[33,34]. Interestingly other aminothiols such as glutathi-
one and cysteinylglycine were found to have the opposite
effects since they have strong antioxidative and anti-
atherogenic action [35-37]. The most important role of
thiol compounds in vivo is their function as redox buf-
fers, regulating protein thiol-disulfide composition in
both cellular and extracellular compartments [19].
Reduced, free oxidized and protein-bound forms of
major thiols constitute the plasma thiol redox status
[38]. In our study we measured both the total and total
free fractions of aminothiols to avoid a direct measure-
ment of the reduced forms which are highly unstable and
therefore the methods of their measurement cannot be
standardized [19,38]. Therefore as was postulated almost
two decades ago by Ueland et al. [38] the ratio of total free
to total aminothiol may reflect a redox thiol status, i.e. an
activity of the major extracellular antioxidant defense sys-
tem. Since in our study the treatment with fenofibrate
shifted an aminothiol balance towards a less prooxidative
pattern it may indirectly show the protective effect of this
agent on cardiovascular system however this concept will
require further confirmation with alternative methods of
oxidative stress measurement.
It has been well proven that dyslipidemia is much
more common in patients with end-stage renal disease
than in subjects with normal or only mildly impaired
Table 3 Plasma concentration of total free aminothiols
(glutathione, homocysteine, cysteine and
cysteinylglycine) at baseline and after the 28-day
treatment with fenofibrate or placebo
Parameter Healthy
controls*
Baseline After
Placebo
After
Fenofibrate
Glutathione
[nmol/mL]
5.3±1.2 3.3±0.9 3.4±1.1 4.2±1.4
#$
Homocysteine
[nmol/mL]
2.6±1.7 6.6±3.9 7.8±5.0 9.0±7.4
##
Cysteine
[nmol/mL]
47±22 160±48 163±47 167±51
Cysteinylglycine
[nmol/ml]
7±2 24±4.5 23±4 25±7
* healthy controls – historic cohort from Bald E et al. [19]
# p=0.01 vs baseline; $ p=0.02 vs placebo
## p=0.04 vs baseline
Figure 3 The ratio of free to total aminothiols (aminothiol redox status) at baseline and after the 28-day treatment with fenofibrate or
placebo.
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uremic dyslipidemia that is characterized by increased
triglyceride and LDL-cholesterol and decreased HDL
cholesterol makes dialysis patients almost ideal candi-
dates for treatment with fibric acid derivatives [10,41].
Unfortunately, most fibrates with the exception of pro-
bucol are excreted with urine and may accumulate in
particular in patients with advanced and end-stage
chronic kidney disease [15,16,42,43]. The fibrates are
also poorly removed by hemodialysis [15]. Therefore the
evidence of the effects on fibrates in chronic kidney dis-
ease from large, randomized trials is missing [41,42] with
the exception of a recent post-hoc analysis from FIELD
study that confirmed the safety and potent lipid-lower-
ing efficacy of fenofibrate but that observation was lim-
ited only to the patients with mildly to moderately
impaired kidney function [44]. In contrast, statins are
less accumulated in case of renal function impairment
and most of them can be safely used even in dialysis
patients after a dose reduction [45]. To avoid any poten-
tial toxicity in this pilot study we decided to reduce a
dose of fenofibrate with its administration limited to dia-
lysis days. This also secured a good compliance since the
patients received the drug only in the dialysis center
upon their arrival for the scheduled dialysis treatment.
In our study no side-effects of fenofibrate were observed
and in particular none of our patients report any such
complaints as muscle weakness that could have indicated
skeletal muscle toxicity. That might be also due to the fact
that we excluded the subjects that were simultaneously
using statins as the risk of rhabdomyolysis is the greatest
when fibrate and statin are used in combination [7,8]. We
observed small but significant increase of creatine kinase.
It is however of note that despite the increase of serum
creatinine kinase its serum levels remained within normal
range. Furthermore another common serum marker of
skeletal muscle toxicity of fibrate, i.e. asparagine amino-
transferase was unchanged during the treatment.
Although our study was carefully designed, controlled
and randomized with a cross-over comparison of a study
medication and placebo it was too small and too short
to investigate any hard-end points. Therefore we were
able to focus only on the surrogate biochemical markers
of inflammation and oxidative stress. Other limitations
of our design are as follows: it was carried out in a single
dialysis center and all the patients were Caucasian, there
was no subgroup analysis based on etiology of kidney
failure. Furthermore no pharmacokinetic study with dif-
ferent doses of study was performed with the measure-
ment of plasma levels of fenofibrate and its active
metabolites. Although only the pharmacokinetic data
could provide the information that the patients were
fully compliant with the treatment any non-adherence is
highly unlikely in case of our study because the dosing
scheme comprised the administration of a study drug
only on dialysis days under a supervision of a staff at the
dialysis unit.
In summary we found that low-dose fenofibrate ther-
apy is an effective treatment of uremic dyslipidemia.
Although the safety profile of fenofibrate has been satis-
factory in this small trial in chronic hemodialysis
patients our findings will require confirmation in a
larger and longer study since the potential toxicity of
fenofibrate may develop over a much longer time of
treatment. Such studies that may lead to more effective
treatment of lipid disorders in end-stage kidney disease
would be very important for our futire clinical practice
since hyperlipidemic patients with end-stage chronic
kidney on long-term dialysis are very difficult to treat
due to frequent side-effects of the drugs and advanced
atherosclerosis due to long-standing uremic milieu.
That was probably the reason why even the statin ther-
apy failed to show any beneficial effect on cardiovascu-
l a re v e n t sa n dm o r t a l i t yi nt h i sp o p u l a t i o ni nm o s tl a r g e
trials such as 4D and Aurora with the recent exception
of the largest SHARP study [46].
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